Pisa syndrome and laryngeal dystonia induced by novel antipsychotics.

Isr J Psychiatry Relat Sci

Division of Psychiatry, Ministry of Health, Mental Health Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Published: February 2012

Objectives: Psychopharmacotherapy with antipsychotics frequently leads to different undesirable extrapyramidal side effects. Tardive dystonia is one of them and some of its forms can be dangerous. Usually tardive dystonia occurs during treatment with typical antipsychotics. The new novel drugs raised great expectations, but this adverse event also has been found among patients treated with different kinds of atypical antipsychotics. Publications about tardive movement disturbances induced by these medications become more and more frequent. Our report does not address the management of the patients tardive dystonia but only illustrates the phenomenon.

Method: We describe here three patients suffering from chronic schizophrenia treated with second generation antipsychotics, who developed dystonic symptoms: one with laryngeal dystonia and two others Pisa syndrome. In the patient with laryngeal dystonia these symptoms appeared after restarting risperidone treatment, in the other patient after diminishing the dosage of risperidone and adding sertindole, and in the third patient the syndrome appeared after beginning ziprasidone.

Conclusions: This case series suggests that atypical antipsychotics may have a causal relationship in the development of different forms of tardive dystonia. Physicians should be aware of this problem and always obtain information about the medication used prior to the appearance of movement disturbance.

Download full-text PDF

Source

Publication Analysis

Top Keywords

tardive dystonia
16
laryngeal dystonia
12
pisa syndrome
8
atypical antipsychotics
8
dystonia
7
antipsychotics
6
tardive
5
syndrome laryngeal
4
dystonia induced
4
induced novel
4

Similar Publications

Introduction: Chorea is a motor manifestation of Huntington's disease (HD), which can lead to decreased functional independence and falls. Even though multiple classes of medications have been used to treat this symptom, only the vesicular monoamine transporter 2 (VMAT2) inhibitors tetrabenazine, deutetrabenazine, and valbenazine have been approved by the FDA for this indication.

Areas Covered: This article reviews the pharmacological properties, clinical efficacy, safety, and tolerability of valbenazine in the treatment of chorea in HD.

View Article and Find Full Text PDF

Optimal botulinum toxin therapy of dystonia in Germany: what would it cost?

J Neural Transm (Vienna)

December 2024

IAB - Interdiciplinary Working Group for Movement Disorders, Hamburg, Germany.

Botulinum toxin (BT) therapy is the therapy of choice for most forms of dystonia. We want to describe its costs, if all dystonia patients in Germany would have access to optimal BT therapy. For this, we combined the latest data on epidemiology of dystonia and dosing of BT therapy for dystonia.

View Article and Find Full Text PDF

Vesicular monoamine transporter 2 inhibitors (VMAT2i) are currently Food and Drug Administration-approved for the treatment of Huntington disease chorea and tardive dyskinesia. Additionally, they are often used for other hyperkinetic movement disorders in clinical practice. Due to a lack of head-to-head clinical trials, management of VMAT2i in the clinical setting may be unclear and rely on the clinical experience of the practitioner.

View Article and Find Full Text PDF

Cannabigerol Mitigates Haloperidol-Induced Vacuous Chewing Movements in Mice.

Neurotox Res

December 2024

Department of Physiology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.

Chronic use of typical antipsychotics can lead to varying motor effects depending on the timing of analysis. Acute treatment typically induces hypokinesia, resembling parkinsonism, while repeated use can result in tardive dyskinesia, a hyperkinetic syndrome marked by involuntary orofacial movements, such as vacuous chewing movements in mice. Tardive dyskinesia is particularly concerning due to its potential irreversibility and associated motor discomfort.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!